Treatment of Patients with Multiple Sclerosis Transitioning Between Relapsing and Progressive Disease.

CNS Drugs · 2023 · PMC9829585 · PMID 36598730

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach significanceno p-value reported

Significant effects on CDP were only observed in comparison to placebo and only in one of the two FREEDOMS trials, while FREEDOMS II and the active comparator controlled trials of fingolimod, ozanimod and ponesimod failed to reach significance regarding this outcome.

also in 4,113 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.